Abstract:
Although vascular dementia (VaD) represents the second most common cause of dementia after Alzheimer's disease (AD) in the elderly, and is referred to as the “silent epidemic of the twenty-first century,” there is still a controversy on terminology, classification, and diagnostic criteria of VaD. The diagnosis of VaD resides on diagnostic clinical criteria determining (1) a cognitive impairment, (2) the presence of cerebrovascular disease, and (3) specifically in poststroke or multi-infarct dementia, a temporal relationship between these. The search for a reliable biochemical test hel** in the diagnosis of VaD is so far not available. Several vascular risk factors have a role in the development of VaD and their identification and treatment are among the major aspects of VaD management. A new line of research in this field is the study of genetic factors underlying vascular cognitive impairment which are: (1) genes predisposing to cerebrovascular disease, and (2) genes that influence brain tissue responses to cerebrovascular lesions. Evidence in favor of a coexistence of vascular and degenerative components in the pathogenesis of dementia in an elderly population comes from neuropathological and epidemiological studies. There is now a great debate whether VaD and AD are more than common coexisting unrelated pathologies or, instead, represent different results of synergistic pathological mechanisms. Current available medications for the treatment of VaD include acetylcholinesterase inhibitors for mild to moderate cases, and memantine, an NMDA-receptor antagonist. However, therapeutic preventive approaches aiming at reducing incident VaD by targeting patients at risk of cerebrovascular disease (primary prevention), or acting on patients after a stroke (secondary prevention) to prevent stroke recurrence and the progression of brain changes associated with cognitive impairment are the mandatory strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ADDTC:
-
Alzheimer Disease Diagnostic and Treatment Centers
- AD:
-
Alzheimer's disease
- MID:
-
multi-infarct dementia
- sVaD:
-
subcortical vascular dementia
- VaD:
-
vascular dementia
- VCI:
-
vascular cognitive impairment
References
Adair J, Charlie J, Dencoff JE, Kaye JA, Quinn JF, et al. 2004. Measurement of gelatinase B (MMP-9) in cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Brain 35: 159–162.
Ballard CG, Burton EJ, Barber R, Stephens S, Kenny RA, et al. 2004. Ninds airen neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology 63: 983–988.
Binswanger O. 1894. Die Abgrenzung der allgemeinen progressiven paralyse. Berl Klein Wochenschr 31: 1102–1205, 1137-1139, 1180-1186.
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, et al. 2004. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24 week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34: 2323–2332.
Briani C, Cagnin A, Gallo L, Toffanin E, Varagnolo M, et al. 2005. Anti-heparan sulphate antibodies and homocysteine: Markers of vascular pathology? J Neurol Sci 229-230: 215–218.
Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, et al. 1992. Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer disease diagnostic and treatment centers (ADDTC). Neurology 42: 473–480.
Craig D, Birks J. 2005. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2: CD004744.
Craig D, Birks J. 2006. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 1: CD004746.
Danysz W, Parsons CG, Mobius HJ, Stoffler A, Quack G. 2000. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease: A unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2: 85–97.
Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K. 2004. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35: 1010–1017.
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, et al. 2002. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomized trial. Lancet 359: 1283–1290.
Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, et al. 2003. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 25: 1765–1782.
Fein G, Di Sclafani V, Tanabe J, Cardenas V, Weiner MW, et al. 2000. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 55: 1626–1635.
Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, et al. 2002. The prevention of dementia with antihypertensive treatment: New evidence from the systolic hypertension in Europe (syst-eur) study. Arch Intern Med 162: 2046–2052.
Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, et al. 2000. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Neurology 54: S4–S9.
Gorelick PB, Roman G, Mangone CA. 1994. Vascular dementia. Handbook of Neuroepidemiology, Gorelick PB, Alter MA, editors. New York: Mecel Dekker; pp. 197–214.
Hachinski VC, Lassen MA, Marshall J. 1974. Multi-infarct dementia. A cause of mental deterioration in elderly. Lancet 2: 207–210.
Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 288: 2015-2022.
Ikeda M, Hokoishi K, Maki N, Nebu A, Tachibana N, et al. 2001. Increased prevalence of vascular dementia in Japan. Neurology 57: 839–844.
Jellinger KA. 2007. The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113: 349-388.
Leblanc GG, Meschia JF, Stuss DT, Hachinski V. 2006. Genetics of vascular cognitive impairment. The opportunity and the challenges. Stroke 37: 248–255.
Looi JCL, Sachdev PS. 1999. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 53: 670–678.
Lopez-Arieta BJ. 2001. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 1: CD000147.
Luria AR. 1966. Higher cortical function in man. New York: Basic Books.
Malhotra PA, Parton AD, Greenwood R, Husain M. 2006. Noradrenergic modulation of space exploration in visual neglect. Ann Neurol 59: 186–190.
Malouf R, Birks J. 2005. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 1: CD004395.
Malouf M, Grimley EJ, Arcosa SA. 2003. Folic acid with and without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 4: CD004514.
McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, et al. 2001. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 12: 309–313.
McGuinness B, Todd S, Passmore P, Bullock R. 2006. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 19: CD004034.
McShane R, Areosa Sastre A, Minakaran N. 2006. Memantine for dementia. Cochrane Database Syst Rev 3: CD003154.
Moretti R, Torre P, Antonello RM, Cazzato G. 2004. Rivastigmne in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 8: 361–362.
Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, et al. 1996. Risk factors for incident dementia after stroke: Role of hypoxic ischemic disorders. Stroke 27: 1283–1289.
O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, et al. 2003. Vascular cognitive impairment. Lancet Neurol 2: 89–98.
Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. 2002. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM300). Stroke 33: 1834–1839.
Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, et al. 2005. Efficacy and safety of nimodipine in subcortical vascular dementia: A randomized placebo-controlled trial. Stroke 36: 619–624.
Price CC, Jefferson AL, Merino JG, Heilman KM, Libon DJ. 2005. Subcortical vascular dementia: Integrating neuropsychological and neuroradiologic data. Neurology 65: 376–382.
Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, et al. 2007. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 130: 731-739.
Resberg B, Doody R, Stoffler A, Schmitt F, Ferris S, et al. 2003. Memantine in moderate to severe Alzheimer's disease. N Engl J Med 348: 1333–1341.
Roman GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, et al. 2004. Vascular cognitive disorder: A new diagnostic category updating vascular cognitive impairment and vascular dementia. Neurol Sci 226: 81–87.
Roman GC, Tatemichi TK, Erkinjutti T, Cummings JL, Masdeu JC, et al. 1993. Vascular dementia: Diagnostic criteria for research studies. Report of the ninds-airen international workshop. Neurology 43: 250–260.
Royall DR, Roman GC. 2000. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 55: 604–606.
Royall DR, Coder JA, Polk M. 1998. Clox: An executive clock drawing task. J Neurol Neurosurg Psychiatry 64: 588–594.
Sabri O, Ringerstein EB, Hellwig D, Schneider R, Schreckenberger M, et al. 1999. Neuropsychological impairment correlates with hypoperfusion and hypometabolism but not with severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 30: 556–566.
Sachdev P. 1999. Vascular cognitive disorder. Int J Geriatr Psychiatry 14: 402–403.
Selden NR, Gitelman DR, Salamon-Murayama N, Parrsh TB, Mesulam MM. 1998. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121: 2249–2257.
Sever PS, Dahlof D, Poulter N, Wedel H, Beevers G, et al. 2003. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial lipid lowering arm (ASCOT-LLA): A multicentre controlled trial. Lancet 361: 1149–1158.
Slooter AJC, Tang MX, van Duijn CM, Stern Y, Ott A, et al. 1997. Apolipoprotein E 4 and the risk of dementia with stroke: A population-based investigation. JAMA 277: 818–821.
Suribhatla S, Dennis MS, Potter JF. 2005. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 229-230: 147–150.
Traykov L, Rigaud AS, Caputo L, Couderc R, Coste J, et al. 1999. Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurology 6: 415–421.
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, et al. 2003. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163: 1069–1075.
Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. 2002. Prevalence and risk factors of silent brain infarcts in the population based Rotterdam scan study. Stroke 33: 21–25.
Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagst WJ, et al. 2000. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 60: 658–659.
Wilcock G, Mobius HJ, Stoffler A, MMM 500 group. 2002. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17: 297–305.
Wilkinson D, Dody R, Helme R, Taubman K, Minzer J, et al. 2003. Donepezil 308 study group. Donepezil in vascular dementia: A randomized, placebo-controlled study. Neurology 61: 479–486.
World Health Organization 1993. International classification of diseases, Tenth Revision. Geneva: World Health Organization.
Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, et al. 2005. Cache county study investigators. Do statins reduce risk of incident dementia and Alzheimer's disease? The Cache County Study. Arch Gen Psych 62: 217–224.
Acknowledgments
This work was supported in part by a grant from the Italian Ministry of Health within the Finalized Research Projects 2006–2007 (type II, no. 107).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this entry
Cite this entry
Cagnin, A., Battistin, L. (2007). Vascular Dementia. In: Lajtha, A., Youdim, M.B.H., Riederer, P., Mandel, S.A., Battistin, L. (eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-30377-2_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-30377-2_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-30344-4
Online ISBN: 978-0-387-30377-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences